Published Online
on September 20, 2004

A more recent version of this article appeared on September 28, 2004

This Article Full Text (PDF) All Versions of this Article: 110/13/1774    most recent 01.CIR.0000142864.83780.81v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krishnan, E. Articles by Singh, G. Search for Related Content PubMed PubMed Citation Articles by Krishnan, E. Articles by Singh, G. Related Collections Acute myocardial infarction Epidemiology

Submitted on February 7, 2004
Revised on May 20, 2004
Accepted on May 24, 2004

Declines in Mortality From Acute Myocardial Infarction in Successive Incidence and Birth Cohorts of Patients With Rheumatoid Arthritis

Eswar Krishnan MD, MPhil^*, Vijaya Bharathi Lingala PhD, and Gurkirpal Singh MD

From Stanford University, Division of Immunology (E.K., V.B.L.), and the Divisions of Gastroenterology and Hepatology (G.S.), Department of Medicine, 1000 Welch Rd, Suite 203, Palo Alto, Calif.

^* To whom correspondence should be addressed. E-mail: eswar_krishnan{at}hotmail.com.

Background--Patients with rheumatoid arthritis are at high risk for acute myocardial infarction (AMI). The treatment of rheumatoid arthritis has become more intensive over the past 2 decades, resulting in tighter control of inflammation and lower levels of disability. The impact of this on atherosclerotic cardiovascular diseases is not known.

Methods and Results--Death rates from AMI in a cohort of 3862 patients with rheumatoid arthritis followed up from 1980 to 1997 were studied. Time trends in AMI mortality among successive incidence and birth cohorts were examined by use of multivariable Poisson regression models and by comparing standardized mortality ratios. The mean age was 56 years in this predominantly female cohort (76%), and median disease duration was 6.5 years. During the period of observation, the use of methotrexate increased substantially, whereas that of prednisone was relatively stable. Over the 22 209 person-years of observation, there were 157 deaths as a result of AMI, with a death rate of 7.06 per 1000 person-years. Mortality rates were higher in older age groups and in men. After adjustment for age, sex, race, and disease duration, the risk of AMI declined in successive incidence years (relative risk, 0.94; 95% CI, 0.92 to 0.96). Patients with rheumatoid arthritis incident after 1990 did not have excess AMI mortality compared with general population. Declines in mortality trends were observed in successive birth cohorts as well.

Conclusions--Mortality as a result of AMI among patients with rheumatoid arthritis has declined over time.

Key words: myocardial infarction • rheumatoid arthritis • mortality • risk • trend

This article has been cited by other articles:

				U. Bergstrom, L. T. H. Jacobsson, and C. Turesson Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden Rheumatology, December 1, 2009; 48(12): 1600 - 1605. [Abstract] [Full Text] [PDF]

				S. L. Westlake, A. N. Colebatch, J. Baird, P. Kiely, M. Quinn, E. Choy, A. J. K. Ostor, and C. J. Edwards The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review Rheumatology, November 27, 2009; (2009) kep366v1. [Abstract] [Full Text] [PDF]

				M. J. Roman and J. E. Salmon Cardiovascular Manifestations of Rheumatologic Diseases Circulation, November 13, 2007; 116(20): 2346 - 2355. [Full Text] [PDF]

				L. Carmona, M. A. Descalzo, E. Perez-Pampin, D. Ruiz-Montesinos, A. Erra, T. Cobo, J. J Gomez-Reino, and on behalf of the BIOBADASER and EMECAR Groups All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists Ann Rheum Dis, July 1, 2007; 66(7): 880 - 885. [Abstract] [Full Text] [PDF]

				D H Solomon, N J Goodson, J N Katz, M E Weinblatt, J Avorn, S Setoguchi, C Canning, and S Schneeweiss Patterns of cardiovascular risk in rheumatoid arthritis Ann Rheum Dis, December 1, 2006; 65(12): 1608 - 1612. [Abstract] [Full Text] [PDF]

				A. A. Quyyumi Inflamed Joints and Stiff Arteries: Is Rheumatoid Arthritis a Cardiovascular Risk Factor? Circulation, September 12, 2006; 114(11): 1137 - 1139. [Full Text] [PDF]

				K M J Douglas, A V Pace, G J Treharne, A Saratzis, P Nightingale, N Erb, M J Banks, and G D Kitas Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome Ann Rheum Dis, March 1, 2006; 65(3): 348 - 353. [Abstract] [Full Text] [PDF]

				M. J. Roman, E. Moeller, A. Davis, S. A. Paget, M. K. Crow, M. D. Lockshin, L. Sammaritano, R. B. Devereux, J. E. Schwartz, D. M. Levine, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med, February 21, 2006; 144(4): 249 - 256. [Abstract] [Full Text] [PDF]

				F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]

				N Goodson, J Marks, M Lunt, and D Symmons Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s Ann Rheum Dis, November 1, 2005; 64(11): 1595 - 1601. [Abstract] [Full Text] [PDF]

				R Gerli and N J Goodson Cardiovascular involvement in rheumatoid arthritis Lupus, September 1, 2005; 14(9): 679 - 682. [Abstract] [PDF]

				J. Frostegard Atherosclerosis in Patients With Autoimmune Disorders Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1776 - 1785. [Abstract] [Full Text] [PDF]